Active Surveillance for Low-risk Prostate Cancer: Developments to Date

Active surveillance (AS) for low-risk prostate cancer (PCa) is attracting increased scientific interest due to better understanding of the natural course of PCa and to rapid technological developments in the diagnosis and treatment of early disease. There is no consensus on the optimal method of selecting men for AS with traditional markers and the role of new histologic, proteomic, or genetic markers. The role of new imaging modalities also...